Diabetes Drug, Victoza, May Have Weight Loss Benefits, but Allegedly Linked to an Increase Risk of Pancreatic Cancer
Posted in Mass Torts
Victoza (liraglutide), an injectable Type II diabetes drug, which works by stimulating insulin production by the pancreas, received approval from the U.S. Food and Drug Administration (“FDA”) in 2010. When taken in high doses (3 milligrams), Victoza, manufactured by Novo Nordisk, has been shown to help individuals lose weight. The… Continue reading